Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
Authors
Keywords
-
Journal
Frontiers in Medicine
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-24
DOI
10.3389/fmed.2020.569215
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gout
- (2019) Nicola Dalbeth et al. Nature Reviews Disease Primers
- Asymptomatic hyperuricaemia: a silent activator of the innate immune system
- (2019) Leo A. B. Joosten et al. Nature Reviews Rheumatology
- The systems biology of uric acid transporters
- (2018) Sanjay K. Nigam et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders
- (2018) Jie Lu et al. KIDNEY INTERNATIONAL
- Patients with gout differ from healthy subjects in renal response to changes in serum uric acid
- (2017) Sha Liu et al. JOINT BONE SPINE
- Intestinal tract is an important organ for lowering serum uric acid in rats
- (2017) Yu Yun et al. PLoS One
- Urate Handling in the Human Body
- (2016) David Hyndman et al. Current Rheumatology Reports
- The Molecular Physiology of Uric Acid Homeostasis
- (2015) Asim K. Mandal et al. Annual Review of Physiology
- ABCG2 Dysfunction Increases Serum Uric Acid by Decreased Intestinal Urate Excretion
- (2014) Tappei Takada et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease
- (2013) Hirofumi Yano et al. Clinical and Experimental Nephrology
- The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality
- (2013) David Gustafsson et al. BMC Nephrology
- Common dysfunctional variants in ABCG2 are a major cause of early-onset gout
- (2013) Hirotaka Matsuo et al. Scientific Reports
- The genetics of hyperuricaemia and gout
- (2012) Anthony M. Reginato et al. Nature Reviews Rheumatology
- Gout and its comorbidities: implications for therapy
- (2012) L. K. Stamp et al. RHEUMATOLOGY
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
- (2012) Dinesh Khanna et al. ARTHRITIS CARE & RESEARCH
- Decreased extra-renal urate excretion is a common cause of hyperuricemia
- (2012) Kimiyoshi Ichida et al. Nature Communications
- Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008
- (2011) Yanyan Zhu et al. ARTHRITIS AND RHEUMATISM
- Uric acid, hyperuricemia and vascular diseases
- (2011) Ming Jin Frontiers in Bioscience-Landmark
- ABCG2 is a High-Capacity Urate Transporter and its Genetic Impairment Increases Serum Uric Acid Levels in Humans
- (2011) Akiyoshi Nakayama et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Update on gout: new therapeutic strategies and options
- (2010) Robert Terkeltaub Nature Reviews Rheumatology
- Sevelamer Decreases Serum Uric Acid Concentration through Adsorption of Uric Acid in Maintenance Hemodialysis Patients
- (2009) Iwao Ohno et al. INTERNAL MEDICINE
- Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy
- (2009) F. Preitner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now